|Day Low/High||2.48 / 2.56|
|52 Wk Low/High||0.88 / 3.24|
We initiated one new position and exited another last week, while several other names reported earnings.
BETR and ATRS report March-quarter numbers. Plus, post-call commentary on USA Technologies.
Multiple Drug Device Combination Products Pending FDA Approval
During a busy week of earnings and data, we exited 2 positions and initiated a small one.
We'll see what happens in the way of reaction to Trump's tax policy this afternoon, but if we sell off I'm likely going to be a buyer.
We exited one position and downgraded another as earnings season heated up.
We added a new name to the portfolio as the market took a breather in a shortened trading week.
We beat the benchmark Russell 2000 for the quarter, and we await a busy week on the economic front.
We are keeping an eye on rate-sensitive names for possible buying opportunities, as stocks fell around 1.5% this week.
Investors in Antares Pharma Inc. saw new options begin trading this week, for the November 17th expiration.
We picked up more Abraxas Petroleum on weakness, while the market rebounded slightly after the FOMC announced the anticipated quarter-point rate hike.
With the stock jumping on 4Q results, we'll lower our rating.
We bulked up on Abraxas Petroleum and Yamana Gold on weakness, as the markets pulled back and investors positioned for next week’s FOMC meeting.
We booked some profits in Huntington Bancshares and Builders FirstSource, while markets digested the likelihood of a March rate hike.
We opened a new position in Abraxas Petroleum on its above-average growth potential, as stocks faced selling pressure this week.
We closed out our position in OraSure Technologies for an average gain of 105% gain.
We used some of the proceeds to boost our stake in Jive Software this week. In addition, we initiated a position in drug-delivery system developer, Antares Pharma.
We're initiating a position in drug-delivery system developer Antares Pharma, which we think can double from current levels.